

**17th Annual John Goldman Conference on  
Chronic Myeloid Leukemia: Biology and Therapy  
Lisbon, Portugal  
October 1-4, 2015**

These abstracts are presented in alphabetical order according to the name of the first author.

**BRIEF ORAL COMMUNICATIONS  
CLINICAL POSTERS**

- POSTER 57: Population pharmacokinetics of imatinib in Nigerian patients with chronic myeloid leukaemia: a need for dosage review  
*Babatunde Adeagbo, Oluseye Bolaji, Muheez Durosinmi, Tiwalade Olugbade, Rahman Bolarinwa, Kayode Ogungbenro*
- POSTER 58: Digital PCR (dPCR) reveals heterogeneous BCR-ABL1 transcript levels in CML patients achieving deep molecular response (DMR) with TKIs  
*Simona Bernardi, Andrea Di Palma, Mario Tiribelli, Erika Codarin, Federica Cattina, Simone Perucca, Valeria Cancelli, Michele Malagola, Cristina Skert, Domenico Russo*
- POSTER 59: Development of Xpert® BCR-ABL Ultra, an automated and standardized multiplex assay with required performance characteristics for BCR-ABL1 quantitative measurement on an international reporting scale  
*Gwo-Jen Day, Christina Lockwood, Jacqueline Payton, Geoffrey Uy, Charles Schiffer, Gerald Feldman, Aaron Bossler, Julie Woolworth, Alice Mims, Alba Levitas, Krupa Shridhar, Sandy Huang, Vivian Xiao, Natalie Wu, Michael Bates, Wendy Wong*
- POSTER 60: Outcomes of newly diagnosed chronic phase CML who switch to Imatinib following optimal response to second generation TKI  
*Vamsi Kota, Faud El Rassi, Martha Arellano, Morgan McLemore, Elliott F. Winton, Leonard T. Heffner, Anand Jillella, H. Jean Houry*
- POSTER 61: Four-year minimum follow-up for patients with chronic-phase CML continuing to receive ponatinib in a phase 1 trial  
*Michael Mauro, Moshe Talpaz, Jorge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, Dale L. Bixby, Ian W. Flinn, Thomas J. O'Hare, Simin Hu, Victor M. Rivera, Tim Clackson, Maureen G. Conlan, Frank G. Haluska, Brian J. Druker, Michael W. Deininger*